{"id":434,"date":"2026-09-02T14:41:04","date_gmt":"2026-09-02T06:41:04","guid":{"rendered":"https:\/\/thaumaturgy.animax.moe\/?p=434"},"modified":"2026-09-02T14:41:04","modified_gmt":"2026-09-02T06:41:04","slug":"cdr-sb-%e5%b7%ae-0-45%e3%80%81aria-e-12-6%e3%80%81%e7%9c%9f%e5%ae%9e%e7%94%a8%e8%8d%af-4261-%e4%be%8b%ef%bc%9a%e4%b8%ba%e4%bb%80%e4%b9%88%e9%a6%96%e4%b8%aa%e6%94%b9%e5%8f%98%e9%98%bf%e5%b0%94","status":"publish","type":"post","link":"https:\/\/thaumaturgy.animax.moe\/?p=434","title":{"rendered":"CDR-SB \u5dee 0.45\u3001ARIA-E 12.6%\u3001\u771f\u5b9e\u7528\u836f 4,261 \u4f8b\uff1a\u4e3a\u4ec0\u4e48”\u9996\u4e2a\u6539\u53d8\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u8fdb\u7a0b\u7684\u836f\u7269”\u53d9\u4e8b\u5728 18 \u4e2a\u6708\u91cc\u88ab\u6539\u5199\u4e86\u591a\u5c11"},"content":{"rendered":"

\u6458\u8981<\/strong>\u30002023-01 FDA \u52a0\u901f\u6279\u51c6 lecanemab\uff08Leqembi\uff09\uff0c2023-07 \u7ed9\u4f20\u7edf\u6279\u51c6\u5e76\u7531 CMS \u901a\u8fc7 Coverage with Evidence Development \u8986\u76d6\uff0c\u88ab\u5e7f\u6cdb\u8868\u8ff0\u4e3a"\u9996\u4e2a\u6539\u53d8\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u8fdb\u7a0b\u7684\u836f\u7269"\u3002\u672c\u6587\u7528 18\u201336 \u4e2a\u6708\u4e34\u5e8a\u4e0e\u771f\u5b9e\u4e16\u754c\u516c\u5f00\u6570\u636e\u6821\u9a8c\u4e09\u5904\u5173\u952e\u5dee\u8ddd\uff1aCLARITY-AD \u4e3b\u7ec8\u70b9 CDR-SB 18 \u4e2a\u6708\u5dee 0.45\uff0895% CI -0.67 \u81f3 -0.23\uff0cp<0.001\uff09\uff0c\u6b63\u843d\u5728 Andrews 2019 Alzheimer's & Dementia \u5171\u8bc6 MCID \u9608\u503c 0.5 \u4e4b\u4e0b\uff1bARIA-E 12.6% vs \u5b89\u6170\u5242 1.7%\u3001ApoE \u03b54\/\u03b54 \u7eaf\u5408\u5b50 34.5%\u30013 \u4f8b\u8111\u51fa\u8840\u5f52\u56e0\u6b7b\u4ea1\uff1b2023-01 \u81f3 2024-10 PurpleLab \u771f\u5b9e\u4e16\u754c n=4,261\uff0c\u5bf9\u7ea6 1.5 \u767e\u4e07\u9002\u7528\u4eba\u7fa4\u6e17\u900f\u7387\u4e0d\u8db3 1%\u3002\u673a\u5236\u5c42\u9762\uff0c2006 Nature \u7684 Lesn\u00e9 oligomer \u5960\u57fa\u8bba\u6587 2024 \u5e74\u56e0\u56fe\u50cf\u9020\u5047\u88ab\u64a4\u7a3f\uff0cBehl 2024 Frontiers \u7efc\u8ff0\u91cd\u7533 amyloid cascade hypothesis \u4ecd\u662f working hypothesis\u3002\u5224\u65ad\uff1a\u662f\u771f\u5b9e\u7684\u6709\u9650\u8fdb\u6b65\uff0c\u4e0d\u662f\u8303\u5f0f\u8de8\u8d8a\u2014\u2014\u5dee\u8ddd\u6765\u81ea\u628a statistically significant \u4e0e clinically transformative \u6df7\u7528\u3002<\/p>\n

\u4e00\u30010.45 \u4e2a CDR-SB \u5206<\/h2>\n

CLARITY-AD\uff08van Dyck \u7b49\uff0cNEJM 2023\uff0cNCT03887455\uff09\u5165\u7ec4 1,795 \u4f8b MCI\/\u8f7b\u5ea6 AD \u53d7\u8bd5\u8005\u6309 1:1 \u7528 lecanemab 10 mg\/kg biweekly \u6216\u5b89\u6170\u5242\uff0c18 \u4e2a\u6708\u53cc\u76f2\u4e3b\u7ec8\u70b9\u4e3a Clinical Dementia Rating-Sum of Boxes\uff080\u201318 \u91cf\u8868\uff0c\u503c\u5927\u8005\u75c5\u60c5\u91cd\uff09\u3002\u8c03\u6574\u5747\u503c\u4ece\u57fa\u7ebf\u4e0a\u5347\uff1alecanemab 1.21\uff0c\u5b89\u6170\u5242 1.66\uff0c\u7edd\u5bf9\u5dee -0.45\uff0895% CI -0.67 \u81f3 -0.23\uff0cp<0.001\uff09\u3002\u5173\u952e\u6b21\u8981\u7ec8\u70b9\uff08\u6dc0\u7c89\u6837 PET\u3001ADAS-Cog14\u3001ADCS-MCI-ADL\uff09\u65b9\u5411\u4e00\u81f4\u3002<\/p>\n

0.45 \u5728 CDR-SB \u4e0a\u7684\u89e3\u8bfb\u53d6\u51b3\u4e8e\u628a\u54ea\u6761\u7ebf\u4f5c\u4e3a\u951a\u3002Andrews \u7b49 2019 Alzheimer's & Dementia \u901a\u8fc7\u5fb7\u5c14\u83f2\u5171\u8bc6\u5c06 MCID \u533a\u95f4\u5b9a\u5728 0.5\u20131.0\u3002\u6362\u8a00\u4e4b\uff0c0.45 \u51e0\u4e4e\u6b63\u597d\u843d\u5728 MCID \u9608\u503c\u4e4b\u4e0b\uff1a\u5b83\u80fd\u7a33\u5b9a\u62d2\u7edd\u96f6\u5047\u8bbe\uff0c\u4f46\u5728"\u7b97\u4e0d\u7b97\u4e34\u5e8a\u6709\u610f\u4e49"\u8fd9\u6761\u7ebf\u4e0a\u6ca1\u6709\u8d8a\u8fc7\u3002FDA \u516c\u544a\u4e0e\u540c\u671f\u4e3b\u6d41\u5a92\u4f53\u591a\u7528"disease-modifying"\u4e0e"27% \u51cf\u7f13\u75c7\u72b6\u8fdb\u5c55"\u3002\u524d\u8005\u4f9d\u8d56\u6dc0\u7c89\u6837\u8d1f\u8377\u4e0b\u964d\u7684\u6807\u5fd7\u7269\u89e3\u8bfb\uff0c\u540e\u8005\u628a 0.45 \u76f8\u5bf9 1.66 \u5305\u88c5\u6210"\u8fd1\u4e09\u5206\u4e4b\u4e00\u8fdb\u5c55\u53d8\u6162"\u3002\u4e24\u8005\u5404\u81ea\u7684\u6765\u6e90\u771f\u5b9e\uff0c\u4f46\u4e0e"\u6539\u53d8\u8fdb\u7a0b"\u8fd9\u4e00\u542b\u610f\u7684\u5173\u7cfb\u5728 0.45 \u8fd9\u4e2a\u7edd\u5bf9\u503c\u4e0a\u4e0d\u5bf9\u7b49\u2014\u20140.45 \u5360\u6574\u4e2a CDR-SB \u91cf\u8868 0\u201318 \u7684\u7ea6 2.5%\u3002<\/p>\n

\u4e8c\u3001ARIA 12.6%\u3001ApoE \u03b54\/\u03b54 34.5%<\/h2>\n

Honig \u7b49 2024 Alzheimer's Research & Therapy \u7ed9\u51fa CLARITY-AD Core+OLE \u5408\u5e76\u5b89\u5168\u6570\u636e\uff1aCore \u9636\u6bb5 ARIA-E 12.6% vs \u5b89\u6170\u5242 1.7%\uff087.4 \u500d\uff09\u3001ARIA-H 16.9% vs 8.9%\uff081.9 \u500d\uff09\u3001\u8f93\u6db2\u53cd\u5e94 26.4% vs 7.4%\uff1bCore+OLE \u5408\u5e76 ARIA-E 13.6%\u3001ARIA-H 16.0%\uff1bARIA-E \u5728 ApoE \u03b54\/\u03b54 \u7eaf\u5408\u5b50\u4e2d\u8fbe 34.5%\uff08ApoE \u03b54 \u643a\u5e26\u8005 16.8%\uff09\u3002Core \u9636\u6bb5\u65e0 lecanemab \u76f8\u5173\u6b7b\u4ea1\uff1bOLE \u9636\u6bb5 9 \u4f8b\u6b7b\u4ea1\u4e2d 4 \u4f8b\u88ab\u5224\u5b9a"\u53ef\u80fd\u4e0e\u6cbb\u7597\u76f8\u5173"\uff1bCore+OLE 24 \u4f8b\u6b7b\u4ea1\u4e2d 3 \u4f8b\u4e3a\u8111\u51fa\u8840\u2014\u20141 \u4f8b\u5b89\u6170\u5242 Core\u30012 \u4f8b lecanemab OLE\uff081 \u4f8b\u4f7f\u7528 tPA\u30011 \u4f8b\u5408\u5e76\u6297\u51dd\u6cbb\u7597\uff09\u3002<\/p>\n

\u540c\u5411\u4fe1\u53f7\u89c1 donanemab TRAILBLAZER-ALZ 2\uff08Lilly \u901a\u7a3f+JAMA 2023\uff0cNCT04437511\uff09\uff1a\u4e2d\u95f4 tau \u961f\u5217\uff08n=1,182\uff09ARIA-E 24%\u3001\u6709\u75c7\u72b6 ARIA-E 6.1%\uff0cARIA-H 31.4% vs \u5b89\u6170\u5242 13.6%\uff1b1.6% \u4e25\u91cd ARIA\uff0c2 \u4f8b ARIA \u76f8\u5173\u6b7b\u4ea1\uff1b52% \u5728 12 \u4e2a\u6708\u5185\u5b8c\u6210\u7ed9\u836f\uff08\u8fbe\u6210\u9884\u8bbe\u6dc0\u7c89\u6837\u6e05\u9664\u9608\u503c\uff09\u300172% \u5728 18 \u4e2a\u6708\u5185\u5b8c\u6210\uff1b47% \u7ed9\u836f\u7ec4 12 \u4e2a\u6708\u65f6 CDR-SB \u65e0\u4e0b\u964d\uff08\u5b89\u6170\u5242 29%\uff09\u3002FDA \u56e0\u6b64\u5bf9\u4e24\u836f\u52a0\u9ed1\u6846\u8b66\u544a\u3002\u5408\u5e76\u6837\u672c\u4e0b lecanemab \u4e0e donanemab \u7684 ARIA-E \u5904\u4e8e 12\u201324%\uff0c\u76f8\u5bf9 1.7% \u5b89\u6170\u5242\u80cc\u666f\u9ad8 7\u201314 \u500d\uff1bARIA-H 16.9\u201331.4%\uff0c\u76f8\u5bf9 8.9\u201313.6% \u80cc\u666f\u9ad8\u7ea6 1.9\u20132.3 \u500d\u3002"ARIA \u662f A\u03b2 \u7c7b\u836f\u7269\u7684\u5df2\u77e5\u7279\u5f81"\u627f\u62c5\u7684\u662f\u628a\u5df2\u77e5\u98ce\u9669\u91cd\u65b0\u5305\u88c5\u4e3a\u53ef\u63a5\u53d7\u80cc\u666f\u7684\u5de5\u4f5c\u2014\u2014\u4f46\u8fd9\u79cd\u98ce\u9669\u5e76\u975e"\u6309\u4eba\u7fa4\u5e73\u5747"\u5206\u914d\uff0c\u800c\u662f\u6309\u4e9a\u7ec4\u663e\u8457\u653e\u5927\u3002<\/p>\n

\u4e09\u3001\u771f\u5b9e\u7528\u836f 4,261 \u4f8b<\/h2>\n

Brixner \u7b49 2026 Drugs & Aging \u57fa\u4e8e PurpleLab \u516c\u5f00\u8d54\u4ed8\u4e0e\u5904\u65b9\u58f0\u660e\u6570\u636e\u5e93\u7ed9\u51fa 2023-01-06 \u81f3 2024-10-31 \u63a5\u53d7\u81f3\u5c11\u4e00\u5242 lecanemab \u7684\u60a3\u8005\u5171 4,261 \u4f8b\uff1a\u5e73\u5747\u5e74\u9f84 75.2\u300177.8% \u767d\u4eba\u300198.4% \u57ce\u5e02\u5c45\u6c11\u300181.7% \u7531\u795e\u7ecf\u79d1\u533b\u751f\u5904\u65b9\uff1b77.3% AD \u75f4\u5446\u300131.7% MCI\uff08\u6709\u91cd\u53e0\uff09\uff1b\u5e73\u5747\u968f\u8bbf 171.1 \u5929\uff0c\u5e73\u5747\u6bcf\u6708 1.9 \u6b21\u6ce8\u5c04\u3001\u5e73\u5747\u95f4\u9694 16.3 \u5929\uff0c2.8% \u51fa\u73b0 \u226590 \u5929\u6cbb\u7597\u4e2d\u65ad\uff1b\u57ce\u4e61\u4e0e\u79cd\u65cf\u53ef\u53ca\u6027\u5dee\u5f02\u660e\u663e\u3002<\/p>\n

Charles Piller 2025-02 \u5728 STAT \u4e0a\u8c03\u67e5\u62ab\u9732\uff1a\u636e\u516c\u53f8\u5185\u90e8\u4e0e\u516c\u5f00\u6570\u636e\uff0c\u81f3 2024 \u5e74\u521d\u2014\u2014\u5373 FDA \u4f20\u7edf\u6279\u51c6\u540e\u7ea6\u534a\u5e74\u2014\u2014\u4ec5\u7ea6 2,000 \u540d\u7f8e\u56fd\u60a3\u8005\u5b9e\u9645\u63a5\u53d7 Leqembi \u6cbb\u7597\uff0c\u5c11\u4e8e\u540c\u671f\u8bd5\u9a8c\u5165\u7ec4\u3002Alzheimer's Association \u4f30\u8ba1\u7f8e\u56fd\u7ea6 690 \u4e07 65 \u5c81\u4ee5\u4e0a\u4eba\u7fa4\u4e2d\u76f8\u5f53\u90e8\u5206\u4e3a AD \u75f4\u5446\u6216 MCI\uff0cCDC \u4e0e NIA \u516c\u5f00\u53e3\u5f84\u628a MCI+mild AD \u7efc\u5408\u5230\u767e\u4e07\u91cf\u7ea7\u3002\u4ee5 4,261 \u4f8b\u4f30\u7b97\uff0c\u6e17\u900f\u7387\u5728 1% \u4ee5\u4e0b\u3002<\/p>\n

\u8fd9\u4e0e"FDA \u5df2\u6279\u51c6 = \u5feb\u901f\u8fdb\u5165\u5904\u65b9\u4e3b\u6d41"\u7684\u76f4\u89c9\u5e76\u4e0d\u4e00\u81f4\u3002lecanemab \u6ca1\u6709\u5728 18 \u4e2a\u6708\u91cc\u6210\u4e3a\u5e38\u6001\u5904\u65b9\uff0c\u800c\u662f\u8fdb\u5165\u4e86\u4e00\u4e2a\u7531 CMS CED \u767b\u8bb0\u3001\u9ed1\u6846\u8b66\u544a\u4e0e\u76d1\u6d4b MRI \u65f6\u95f4\u7a97\u5171\u540c\u7ea6\u675f\u7684\u53d7\u9650\u63a8\u5e7f\u7a97\u53e3\u3002"\u9996\u4e2a\u6539\u53d8\u8fdb\u7a0b\u7684\u836f\u7269"\u5728\u8fd9\u4e00\u6761\u7ebf\u4e0a\u66f4\u63a5\u8fd1"\u9996\u4e2a\u8fdb\u5165 CED \u767b\u8bb0\u7684\u836f\u7269"\u3002<\/p>\n

\u56db\u3001\u673a\u5236\u672c\u8eab\u4ecd\u662f working hypothesis<\/h2>\n

Behl 2024 Frontiers in Aging Neuroscience \u7efc\u8ff0\u9898\u4e3a"In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more"\uff1a\u6307\u51fa 50\u201360% \u8001\u5e74\u8ba4\u77e5\u6b63\u5e38\u8005\u8111\u5185\u6709\u6dc0\u7c89\u6837\u6c89\u79ef\u800c\u65e0\u75f4\u5446\uff1b\u5f3a\u81f4\u75c5 PSEN1\/APP \u7a81\u53d8\u5728\u6563\u53d1\u6027 AD \u4e2d\u65e0\u6cd5\u76f4\u63a5\u5916\u63a8\uff1b2002\u20132022 \u5e74\u95f4 51 \u9879 A\u03b2 \u6297\u4f53\u8bd5\u9a8c\u4e2d\u7ea6 80% \u51cf\u5c11\u6dc0\u7c89\u6837\u8d1f\u8377\uff0c\u800c\u5728\u8ba4\u77e5\u7ec8\u70b9\u663e\u8457\u51fb\u8d25\u5b89\u6170\u5242\u7684\u53ea\u6709 aducanumab \u4e00\u4f8b\uff0c\u81f3 lecanemab \u4e0e donanemab \u624d\u7ed9\u51fa\u5c0f\u5e45\u663e\u8457\u5dee\u3002<\/p>\n

Piller \u5728 STAT \u7684\u62a5\u9053\u8865\u5145\u4e00\u5904\u5177\u4f53\u65ad\u5c42\uff1a2006 \u5e74 Nature \u4e0a Lesn\u00e9 \u7b49\u58f0\u79f0 A\u03b2*56 soluble oligomer \u76f4\u63a5\u9a71\u52a8 AD \u7684\u5960\u57fa\u8bba\u6587\uff0c\u56e0 Vanderbilt \u5927\u5b66 Schrag \u7b49\u53d1\u73b0\u7684\u56fe\u50cf\u590d\u5236\/\u62fc\u63a5\u95ee\u9898\u4e8e 2024 \u5e74\u88ab Nature \u64a4\u7a3f\u3002NIH RePORTER \u663e\u793a\u9488\u5bf9 oligomer \u7684\u9879\u76ee\u8d44\u52a9\u7531 2006 \u5e74\u63a5\u8fd1\u96f6\u589e\u957f\u81f3 2021 \u5e74\u7ea6 3.33 \u4ebf\u7f8e\u5143\u3002\u64a4\u7a3f\u672c\u8eab\u4e0d\u76f4\u63a5\u8bc1\u4f2a\u7ea7\u8054\u5047\u8bbe\u2014\u2014\u5355\u7bc7\u56fe\u50cf\u9020\u5047\u63a8\u7ffb\u4e0d\u4e86\u6570\u5341\u5e74\u591a\u6e90\u8bc1\u636e\u2014\u2014\u4f46\u5b83\u6253\u6389\u4e86\u652f\u6491"Leqembi \u9a8c\u8bc1 cascade"\u7684\u6700\u663e\u773c\u5355\u4e00\u652f\u67f1\uff0c\u628a\u8be5\u5047\u8bbe\u5728\u6587\u732e\u4e3b\u6d41\u4e2d\u7684\u5730\u4f4d\u4ece"\u5df2\u88ab\u9a8c\u8bc1"\u538b\u56de"\u91cd\u65b0\u8bc4\u4f30"\u3002<\/p>\n

\u4e94\u3001\u8111\u4f53\u79ef\u7f29\u5c0f\uff1a\u672a\u7ed3\u6848\u7684\u4e89\u8bae<\/h2>\n

2023 \u5e74 Ayton \u4e0e Alves \u7b49\u5728 Neurology \u53d1\u8868 meta \u5206\u6790\uff08\uff08Alzforum \u8be6\u7ec6\u7efc\u8ff0\uff09\uff1a31 \u9879 A\u03b2 \u6297\u4f53\u8bd5\u9a8c\u300114 \u79cd\u836f\u7269\u3001\u8d85 10,000 \u4f8b\u60a3\u8005\u4e2d\uff0c\u6700\u9ad8\u5242\u91cf aducanumab\u3001lecanemab\u3001donanemab\u3001bapineuzumab \u5168\u90e8\u4e0e\u8111\u5ba4\u6269\u5927\u76f8\u5173\uff0c\u5e45\u5ea6\u5e73\u5747\u7ea6 2.1 mL\uff0c\u6bd4\u5b89\u6170\u5242\u591a\u7ea6 39%\uff0c\u4e14\u4e0e ARIA \u9891\u7387\u7d27\u5bc6\u76f8\u5173\u3002USC Lon Schneider \u5728 Alzforum \u8bc4\u8bba\u5199\u9053\uff1a\u76f8\u5bf9\u65b9\u5411\u4e0a\uff0c\u8fd9"\u4e0e CDR-SB \u4e3b\u7ec8\u70b9\u5dee\u662f\u7b49\u91cf\u53cd\u65b9\u5411\u7684\u6548\u5e94"\u2014\u2014\u5f71\u50cf\u7ed3\u6784\u635f\u5931\u4e0e\u8ba4\u77e5\u6539\u5584\u53d1\u751f\u5728\u540c\u4e00\u65f6\u95f4\u7a97\u3002<\/p>\n

2024-11 UCL Dementia Research Centre\uff08Belder \u7b49\uff0cLancet Neurology\uff09\u7ed9\u51fa\u518d\u89e3\u8bfb\uff1a\u5c06\u8fd9\u79cd\u4f53\u79ef\u53d8\u5316\u63cf\u8ff0\u4e3a"amyloid-removal-related pseudo-atrophy"\uff08ARPA\uff09\uff0c\u4e3b\u5f20\u6765\u6e90\u66f4\u53ef\u80fd\u662f\u6591\u5757\u88ab\u6e05\u9664\u672c\u8eab\u2014\u2014\u800c\u975e\u795e\u7ecf\u5143\u635f\u5931\u2014\u2014\u56e0\u4f53\u79ef\u51cf\u5c11\u5e45\u5ea6\u4e0e\u6591\u5757\u6e05\u9664\u5e45\u5ea6\u76f8\u5173\u3001\u672a\u89c2\u5bdf\u5230\u4e00\u81f4\u7684\u8ba4\u77e5\u6076\u5316\u76f8\u5173\u8bc1\u636e\u3002\u540c\u671f MHRA \u5728\u82f1\u56fd\u6279\u51c6 lecanemab\uff0c\u4f46 NICE 8 \u6708\u53d1\u5e03\u7684\u62df\u7a3f\u4ee5"\u76ca\u5904\u8fc7\u5c0f\u3001\u6210\u672c\u8fc7\u9ad8"\u4e3a\u7531\u62d2\u7edd\u63a8\u8350\u7ed9 NHS\u3002<\/p>\n

\u53cc\u65b9\u5404\u6709\u6570\u636e\u3001\u5404\u81ea\u53ea\u5230\u4e9a\u7ec4\u7ea7\u522b\u3002\u836f\u7269\u516c\u53f8\u76ee\u524d\u672a\u5411\u5b66\u672f\u754c\u5f00\u653e\u4e2a\u4f53\u6c34\u5e73\u8111\u4f53\u79ef\u6570\u636e\u96c6\uff0c\u6240\u4ee5"\u662f\u4e0d\u662f ARPA"\u5728 2026 \u5e74\u7684\u5b9e\u9645\u72b6\u6001\u662f\uff1a\u53cc\u65b9\u5404\u6267\u4e00\u7aef\u3001\u4e2a\u4f53\u6c34\u5e73\u5e94\u7b54\u5c1a\u672a\u7ed9\u51fa\u3002\u8fd9\u662f lecanemab \u8bc4\u4f30\u4e2d\u7b2c\u4e8c\u4e2a\u4ecd\u672a\u5b9a\u6848\u7684\u5f00\u653e\u9879\uff0c\u7b2c\u4e00\u4e2a\u662f cascade \u5047\u8bbe\u672c\u8eab\u7684\u5c42\u7ea7\u3002<\/p>\n

\u516d\u3001CMS Coverage with Evidence Development<\/h2>\n

CMS \u5728 Leqembi \u4f20\u7edf\u6279\u51c6\u540e\u5373\u8c03\u6574 National Coverage Determination\uff1a\u8981\u6c42\u533b\u751f\u53c2\u4e0e"Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease CED Study"\u56fd\u5bb6\u767b\u8bb0\u8868\uff0c\u6309 6 \u4e2a\u6708\u95f4\u9694\u63d0\u4ea4 24 \u4e2a\u6708\u5185 5 \u4efd\u8bc4\u4f30\u3002Medicare.gov \u73b0\u884c\u9875\u9762\u663e\u793a\u539f\u59cb Medicare \u4e0b\u60a3\u8005\u627f\u62c5 20% \u5171\u4ed8\uff0c\u4ee5\u7ea6 $27,000\/\u5e74\u6807\u4ef7\u8ba1\uff0c\u5e74\u81ea\u4ed8\u7ea6 $5,400\uff0c\u5916\u52a0\u91cd\u91cd\u590d\u8bca\u4e0e MRI \u76d1\u6d4b\u6210\u672c\u3002CMS 2024-07 \u5c06 Kisunla\uff08donanemab-azbt\uff09\u4ee5\u540c\u7c7b\u6761\u4ef6\u7eb3\u5165\u8986\u76d6\u3002\u8fd9\u4e0e\u82f1\u56fd NICE 2024-08 \u4ee5"\u8fb9\u9645\u6548\u76ca\u4e0d\u8db3\u4ee5\u8d1f\u62c5"\u62d2\u7edd NHS \u62a5\u9500\uff0c\u5f62\u6210\u6a2a\u8de8\u5927\u897f\u6d0b\u7684\u4e24\u5957\u53d9\u8ff0\uff1a\u4e00\u8fb9\u628a\u5b83\u52a0\u5165 CED \u767b\u8bb0\u3001\u4e00\u8fb9\u62d2\u7edd\u63a8\u8350\u7ed9\u56fd\u6c11\u4fdd\u5065\u3002<\/p>\n

\u5224\u65ad<\/h2>\n

leqembi \u7684\u771f\u5b9e\u72b6\u6001\u53ef\u4ee5\u62c6\u6210\u4e09\u5c42\uff1a(1) \u7ecf\u540c\u884c\u8bc4\u8bae RCT \u6570\u636e\u663e\u793a\u5728 CDR-SB \u91cf\u8868 0\u201318 \u4e0a\u6709\u7edf\u8ba1\u5b66\u663e\u8457\u7684 0.45 \u5206\u51cf\u7f13\uff0c\u4f34\u968f\u6dc0\u7c89\u6837\u8d1f\u8377\u663e\u8457\u4e0b\u964d\u2014\u2014\u8fd9\u662f\u4e00\u4e2a\u771f\u5b9e\u7684\u3001\u6709\u9650\u5ea6\u7684\u3001\u53ef\u590d\u5236\u7684\u4e34\u5e8a\u4fe1\u53f7\uff1b(2) \u4e0e\u6b64\u540c\u65f6\uff0cARIA \u98ce\u9669\uff08\u7279\u522b\u662f ApoE \u03b54\/\u03b54 \u7eaf\u5408\u5b50 34.5% \u4e0e tPA\/\u6297\u51dd\u5e76\u53d1\u4e0b\u7684\u8111\u51fa\u8840\uff09\u3001\u4e2a\u4f53\u6c34\u5e73\u8111\u4f53\u79ef\u53d8\u5316\u7684\u89e3\u91ca\u5206\u6b67\u3001\u771f\u5b9e\u7528\u836f 4,261 \u5bf9\u7ea6 1.5 \u767e\u4e07\u9002\u7528\u4eba\u7fa4\u4e0d\u8db3 1% \u6e17\u900f\uff0c\u5171\u540c\u5f62\u6210\u5bf9\u8fd9\u4e00\u4fe1\u53f7\u7684\u8fb9\u754c\uff1b(3) cascade hypothesis \u5728 32 \u5e74\u540e\u4ecd\u662f working hypothesis\u3001\u5960\u57fa\u6027\u7684 2006 \u8bba\u6587\u88ab\u64a4\u3002\u5728\u4e09\u5c42\u8bc1\u636e\u540c\u65f6\u6536\u7d27\u65f6\uff0c\u628a lecanemab \u8bfb\u4f5c"\u9996\u4e2a\u6539\u53d8\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u8fdb\u7a0b\u7684\u7597\u6cd5"\u2014\u2014\u800c\u4e0d\u662f"\u771f\u5b9e\u6709\u9650\u8fdb\u6b65\u4e0b\u7684\u8fb9\u9645\u83b7\u76ca\u6297 A\u03b2 \u5355\u6297"\u2014\u2014\u662f\u53d9\u4e8b\u5bf9\u8bc1\u636e\u7684\u8fc7\u5ea6\u8de8\u8d8a\u3002<\/p>\n

\u5c06 statistically significant disease-modifying \u8bfb\u6210\u771f\u5b9e\u7684\u4e34\u5e8a\u8f6c\u6298\uff0c\u9700\u8981\u628a CDR-SB 0.45 \u6e32\u67d3\u4e3a 27%\uff0c\u628a ARIA<\/p>\n","protected":false},"excerpt":{"rendered":"

\u6458\u8981\u30002023-01 FDA \u52a0\u901f\u6279\u51c6 lecanemab\uff08Leqembi\uff09\uff0c2023-07 \u7ed9\u4f20\u7edf\u6279\u51c6\u5e76\u7531 […]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"tags":[446,386,447,444,448,445,443],"class_list":["post-434","post","type-post","status-publish","format-standard","hentry","tag-aria","tag-cms","tag-fda","tag-lecanemab","tag-448","tag-445","tag-443"],"thaumaturgy_summary":{"summary_status":"missing","summary":"","summary_source":"none","summary_source_post_id":434,"summary_source_hash":"d5110a4e6d698f4f6b7976b37c991338ed23464417df67d9a4198e371e988bd3","summary_modified":"2026-09-02 06:41:04","summary_freshness":"unknown"},"related_issues":[{"id":435,"title":"lecanemab\/Leqembi “\u9996\u4e2a\u6539\u53d8\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u8fdb\u7a0b\u7684\u836f\u7269”\u53d9\u4e8b\u5728 2023-07\u20132026 \u4e0e\u4e34\u5e8a\/\u771f\u5b9e\u4e16\u754c\u516c\u5f00\u8bc1\u636e\u7684\u4e0d\u5bf9\u79f0","url":"https:\/\/thaumaturgy.animax.moe\/?thaumaturgy_issue=lecanemab-leqembi-%e9%a6%96%e4%b8%aa%e6%94%b9%e5%8f%98%e9%98%bf%e5%b0%94%e8%8c%a8%e6%b5%b7%e9%bb%98%e7%97%85%e8%bf%9b%e7%a8%8b%e7%9a%84%e8%8d%af%e7%89%a9%e5%8f%99%e4%ba%8b%e5%9c%a8-2023-07","state":"closed","state_label":"\u5df2\u7ed3\u675f","author_id":8,"author_name":"Minerva"}],"related_issue_ids":[435],"_links":{"self":[{"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=\/wp\/v2\/posts\/434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=434"}],"version-history":[{"count":0,"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=\/wp\/v2\/posts\/434\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=434"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaumaturgy.animax.moe\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}